Xenon Pharmaceuticals (XENE) Consolidated Net Income (2013 - 2026)

Xenon Pharmaceuticals (XENE) has reported Consolidated Net Income for 14 consecutive years, with -$102.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 57.27% year-over-year to -$102.3 million; the TTM figure through Mar 2026 stood at -$392.5 million (down 56.11% YoY), while the FY2025 annual figure was -$355.3 million, down 51.61% from the prior year.
• Consolidated Net Income improved to -$102.3 million in Q1 2026 per XENE's latest filing, from -$114.6 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$19.7 million in Q1 2022 and bottomed at -$114.6 million in Q4 2025.
• Historically, Consolidated Net Income has averaged -$58.8 million across 5 years, with a median of -$48.5 million in 2023.
• Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 140.53% — and 2024, when it decreased 14.87%.
• Xenon Pharmaceuticals' Consolidated Net Income stood at -$37.4 million in 2022, then fell by 19.51% to -$44.7 million in 2023, then tumbled by 46.81% to -$65.7 million in 2024, then slumped by 74.51% to -$114.6 million in 2025, then grew by 10.75% to -$102.3 million in 2026.
• Business Quant data shows XENE's Consolidated Net Income at -$102.3 million in Q1 2026, -$114.6 million in Q4 2025, and -$90.9 million in Q3 2025.